• search
Banner

Antibody Drug Conjugate Services

Antibody Drug Conjugate Services

Antibody, linker-payload, conjugation and analytics – we provide a one-stop solution for ADC discovery and development

We understand the dynamic nature of the current ADC technology landscape and the complexities associated with it. Our team is well versed with a wide range of ADC technologies and is capable of adopting new technologies to support our client needs. We also provide expertise to develop novel liker technologies and cytotoxic payload optimization.

Linker Technologies:

We offer ADC linkers based on their drug release mechanism

  • Cleavable and non-cleavable linkers
  • Self-immolative tracer free linkers
  • Peptide linkers

Conjugation technologies:

  • Amine (Lys) conjugation
  • Thiol (Cys) conjugation
  • Site specific conjugation
  • Enzymatic conjugation

Payloads:

  • Cytotoxic, non-cytotoxic and biologic payloads
  • Classes of cytotoxic payloads handled: Autistatins (MMAE & MMAF), Tubulysin, PBD dimer, Maytansin (DM1), Duocarmycin, SN38, etc.

ADC Discovery and Development:

Discovery programs are customized keeping the target biology and mechanism of action in mind. Specific screening strategies are designed and employed at a stage as early as antibody generation. Some of the early stage activities include screening and design of mAbs for internalization (or lack of it), effector function, off-site localization, half-life, etc. Rapid and comprehensive scouting of the linker-payload technology space can be plugged-in to identify the most desirable combinations of mAb, linker-payload and conjugation strategies. Stage appropriate in vitro screening and detailed evaluation of lead ADC molecules is carried out using customized assay platforms. We also provide in vivo therapeutic evaluation, PK and rodent toxicology assessment support for ADC candidates with appropriate bioanalytical methods customized for each program. Conjugation and purification process development takes into account each component of the ADC molecule. Quality, scalability, safety and cost-effectiveness concerns are addressed at each stage of process development.

ADC Analysis

A biomolecule is complex as an ADC and demands through analytical assessment to ensure safety and quality.

Routinely Determined Attributes are:

  • Aggregation
  • Fragmentation
  • Free-drug
  • DAR average
  • Conjugation site
  • Endotoxin
  • Antigen binding affinity
  • In vitro potency
 

Virtual Tour

 

Connect with our scientific experts for your drug discovery, development, and manufacturing needs

We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.

Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.

Country

section

CAPTCHA
この質問はあなたが人間の訪問者であるかどうかをテストし、自動化されたスパム送信を防ぐためのものです。

rightCaptcha

寡核苷酸作为一种新型治疗方式

JULY 02, 2021

寡核苷酸作为一种新型治疗方式

寡核苷酸作为一种治疗类别是发现用于治疗人类疾病的新的重要治疗剂的革命性方法。基于 RNA 的干预有时适用于其他方式不起作用的情况。例如,它可能有助于治疗先天性新陈代谢错误、遗传疾病和罕见病 寡核苷酸疗法是将化学修饰的寡核苷酸用于治疗目的。寡核苷�...

Read More

Methoxy Polyethylene Glycol (m-PEGs)

Aurigene Pharmaceutical Services is a leader in the synthesis of activated MethoxyPolyethyleneGlycol(m-PEGs), With a comprehensive product range and customized services. ...

Read More

Base mediated spirocyclization of quinazoline: one-step synthesis of spiro-isoindolinone dihydroquinazolinones

2020

A novel approach for the spiro-isoindolinone dihydroquinazolinones has been demonstrated from 2- aminobenzamide and 2-cyanomethyl benzoate in the presence of KHMDS as a base to get moderate yields. The reaction has been screened in various bases followed by solvents and a gram scale reaction has also been executed under the given conditions. Based on the controll...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack